Full data view for gene PIGL

Information The variants shown are described using the NM_004278.3 transcript reference sequence.

3 entries on 1 page. Showing entries 1 - 3.
Legend   How to query  

Effect     

Exon     

AscendingDNA change (cDNA)     

RNA change     

Protein     

Allele     

Classification method     

Clinical classification     

DNA change (genomic) (hg19)     

DNA change (hg38)     

Published as     

ISCN     

DB-ID     

Variant remarks     

Reference     

ClinVar ID     

dbSNP ID     

Origin     

Segregation     

Frequency     

Re-site     

VIP     

Methylation     

Template     

Technique     

Tissue     

Remarks     

Disease     

ID_report     

Reference     

Remarks     

Gender     

Consanguinity     

Country     

Population     

Age at death     

VIP     

Data_av     

Treatment     

Panel size     

Owner     
+/. - c.262C>T r.(?) p.(Arg88Cys) Unknown - pathogenic g.16137311C>T g.16233997C>T - - PIGL_000016 Compound heterozygous variants in the PIGL gene. This is a missense (c.262C > T; p.Arg88Cys; R88C) variant. in silico analysis predicted it as likely damaging the protein structure and function. - - - Germline/De novo (untested) - - - - - DNA SEQ - Commercially available multigene panel for intellectual disability (GeneDx), Sanger sequencing  HPMRS1;GPIBD2 Patient 1 PubMed: Altassan et al., 2018 Individual presented with the main features of HPMRS; developmental delay, cognitive impairment, seizure disorder, skeletal deformities, and high alkaline phosphatase.  M no - - >10y - - Anti-epileptic medications 1 Philippe Campeau
+/. - c.262C>T r.(?) p.(Arg88Cys) Unknown - pathogenic g.16137311C>T g.16233997C>T - - PIGL_000016 Compound heterozygous variants in the PIGL gene. This is a missense (c.262C > T; p.Arg88Cys; R88C) variant. in silico analysis predicted it as likely damaging the protein structure and function. - - - Germline/De novo (untested) - - - - - DNA SEQ - Commercially available multigene panel for intellectual disability (GeneDx), Sanger sequencing  HPMRS1;GPIBD2 Patient 1 PubMed: Altassan et al., 2018 Individual presented with the main features of HPMRS; developmental delay, cognitive impairment, seizure disorder, skeletal deformities, and high alkaline phosphatase.  M no - - >10y - - Anti-epileptic medications 1 Philippe Campeau
+/. - c.262C>T r.(?) p.(Arg88Cys) Unknown - pathogenic g.16137311C>T g.16233997C>T - - PIGL_000016 Compound heterozygous. This second variant is a missense (c.262C > T; p.Arg88Cys; R88C) variant. In silico analysis predicted it as likely damaging the protein structure and function. - - - Germline/De novo (untested) - - - - - DNA SEQ - Commercially available multigene panel for intellectual disability (GeneDx), Sanger sequencing  HPMRS1;GPIBD2 Patient 2 PubMed: Altassan et al., 2018 Patient 1's younger brother M no - - >04y - - Anti-epileptic medications. Surgical correction of strabismus. 1 Philippe Campeau
Legend   How to query  


Screenscraping/webscraping (downloading large amounts of data using scripts) is strictly prohibited.
Use our APIs to retrieve data.